TY - JOUR
T1 - Temozolomide-induced rna interactome uncovers novel lncrna regulatory loops in glioblastoma
AU - Fritah, Sabrina
AU - Muller, Arnaud
AU - Jiang, Wei
AU - Mitra, Ramkrishna
AU - Sarmini, Mohamad
AU - Dieterle, Monika
AU - Golebiewska, Anna
AU - Ye, Tao
AU - Dyck, Eric Van
AU - Herold-Mende, Christel
AU - Zhao, Zhongming
AU - Azuaje, Francisco
AU - Niclou, Simone P.
N1 - Funding Information:
Funding: This work was supported by the Luxembourg Institute of Health (ADAPT project of SPN), the Fonds National de la Recherche (FNR) of Luxembourg (CIRCUITOMA, INTER/MOBILITY/13/6548771 grant to FA), the FNRS-Télévie (CREG n0 7.4592,14, Link-GBM n0 7.4570.16, grants to SPN, SF and MS), and the Fondation Cancer of Luxembourg (INCOMING, grant to SF). ZZ was partially supported by National Institutes of Health grants (R01LM012806) and the Cancer Prevention and Research Institute of Texas (CPRIT RP180734 and RP170668).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/9
Y1 - 2020/9
N2 - Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma (GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet, their contribution to the transcriptional response to drugs is less understood. Here, we performed RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for regulatory mechanisms, we integrated thousands of molecular associations stored in public databases to generate a background “RNA interactome”. Our systems-level analysis uncovered a coordinated program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs, miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM. The computational modeling used to identify regulatory circuits underlying drug response and prioritizing gene candidates for functional validation is applicable to other datasets.
AB - Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma (GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet, their contribution to the transcriptional response to drugs is less understood. Here, we performed RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for regulatory mechanisms, we integrated thousands of molecular associations stored in public databases to generate a background “RNA interactome”. Our systems-level analysis uncovered a coordinated program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs, miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM. The computational modeling used to identify regulatory circuits underlying drug response and prioritizing gene candidates for functional validation is applicable to other datasets.
KW - Chemoresistance
KW - Glioblastoma
KW - LncRNA
KW - Regulatory circuit
KW - Temozolomide
KW - Transcriptome
UR - https://www.scopus.com/pages/publications/85090595455
UR - https://www.ncbi.nlm.nih.gov/pubmed/32927769
U2 - 10.3390/cancers12092583
DO - 10.3390/cancers12092583
M3 - Article
C2 - 32927769
AN - SCOPUS:85090595455
SN - 2072-6694
VL - 12
SP - 1
EP - 18
JO - Cancers
JF - Cancers
IS - 9
M1 - 2583
ER -